Download Free Current Management Of The Menopause Book in PDF and EPUB Free Download. You can read online Current Management Of The Menopause and write the review.

In the next few decades, an estimated one billion women will reach menopause. They will depend on the preventative measures, management, and advice provided to them by their gynecologist or general practitioner. At a time when doubts and criticisms have been raised concerning the real benefit and the justification of peri- to postmenopausal estroge
An up-to-date clinically focused text written to answer even the most difficult obstetrics and gynecology question A Doody’s Core Title for 2021! The single-source OB/GYN resource acclaimed for its currency, comprehensiveness, and strong focus on the practical aspects of clinical diagnosis and patient management Expanded and extensively updated to reflect the latest research and advances – including the concepts of precision medicine Of value to medical students, residents, and practicing physicians who will find this an outstanding guide to the management of common and uncommon conditions Ready-to-apply coverage of more than 1,000 diseases and disorders Strikes the perfect balance between brevity and clinical necessity, delivering exactly the amount of information needed for quick diagnosis, effective treatment, and improved outcomes Strong emphasis on disease prevention and evidence-based medicine Hundreds anatomic drawings, image studies, diagrams, charts, and graphs NEW CHAPTER on Benign Disorders of the Uterine Corpus; Cardiac Disorders in Pregnancy and Pulmonary Disorders in Pregnancy are now two separate chapters for more detailed, focused coverage of these important topics Quick-access design facilities use at the point of care
Clinical Reproductive Medicine and Surgery is the new, definitive resource in reproductive medicine. This unique text offers detailed discussion on both the medical and surgical management of reproductive disorders, as well as coverage of associated imaging modalities. Included are chapters on Reproductive Genetics, Management of Endometriosis (including interventional radiology), Ultrasonography and Sonohysterography, Preservation of Fertility, and Recurrent Pregnancy Loss. The book also features an accompanying DVD with additional images and video loops. A resource every practitioner interested in Reproductive Endocrinology and Infertility needs! Offers detailed discussion of medical and surgical management of reproductive disorders ... No other text offers coverage of both medical and surgical management in one resource. Covers gynecologic disorders that impact fertility--an important aspect of identifying fertility issues, not included in major competition Section on basic reproductive biology ... Not overly detailed -- Written for a clinician to understand how to practice reproductive medicine Section on reproductive imaging ... Unique to this text - includes US and MRI of the reproductive organs Algorithm in each chapter ... 4-color throughout ... Demonstrates the appropriate clinical investigation and management ... Offers attractive layout and best views of surgical procedures Perform reproductive surgery procedures with step-by-step guidance on intrauterine device insertion and laparoscopic surgery with detailed images and videos on the accompanying dvd
This updated second edition of Diagnosis and Management of Ovarian Disorders provides thorough, yet succinct insight into the ever-changing realm of ovarian disorders. It presents a novel multidisciplinary approach to the subject as described by clinicians, surgeons, pathologists, basic scientists and related medical researchers. Topics covered include reproductive technology, early diagnosis of ovarian cancer, and management of menopause among others. The breadth of information provided by this book will appeal to clinicians and researchers involved in the study and treatment of ovarian disorders.KEY FEATURES* Includes updated information on early diagnosis of ovarian cancer* Reviews new diagnostic techniques for ovarian disorders* Discusses latest information on reproductive technology* Presents translational treatment linking laboratory research with clinical medicine
In the first edition of this important bestselling book, praised by Newsday as “the bible for a whole generation of menopausal women,” renowned physician and pioneering women’s health advocate Dr. Susan Love warned about the potential dangers of the long-term prescription of hormone replacement therapy. Her insightful words of caution have been backed up by the stunning results of the recent studies on hormone replacement. In this revised edition, Dr. Love offers a remarkably clear set of guidelines as to what the studies have shown about the risks regarding heart disease, breast cancer, stroke, and other conditions, and what effect hormone therapy has on osteoporosis. She offers definitive expert advice about whether or not to go on hormone replacement therapy and, if so, for how long, as well as how to taper off hormones; and she introduces the alternative methods for treating the symptoms of menopause. Dr. Love stresses that menopause is not a disease that needs to be cured—it is a natural life stage, and every woman ought to choose her own mix of options for coping with symptoms. A questionnaire about your own health history and life preferences helps you develop a program that will best fit your unique needs. With clarity and compassion, she walks you through every option for both the short and the long term, including: • lifestyle changes (diet, exercise, and stress management) • alternative therapies (including herbs and homeopathic remedies) • available medications other than hormones
EUROPEAN PRACTICE IN GYNAECOLOGY AND OBSTETRICT is a series of books conceived and endorsed by the European Board and College of Obstetrics and Gynaecology (EBCOG). Its aim is to provide up-to-date, evidence-based information that represents the consensus of opinion among leading European experts in the field, as part of the overall aim of standardising training and practice in order to ensure quality care and facilitate exchange among physicians in all parts of Europe and the rest of the world.
The interplay of hormones, health and behavior across the female life cycle, especially during the menopausal transition, poses a special challenge to health care professionals.Written by experts, this book brings together the knowledge gained on the menopausal transition from clinical experience and medical research. Topics like 'what to expect' from the menopausal transition, sexuality, sociocultural changes, impact of life stressors, and emergence of depression are discussed. The physiology of thermoregulation and the occurrence of hot flashes are reviewed for a better understanding of vasomotor complaints. Another chapter offers an update on hormonal and nonhormonal treatment strategies by presenting an overview of the management of mood and anxiety during the menopausal transition. The emergence of psychotic symptoms associated with peri- and postmenopausal changes in sex hormone levels is also addressed. Lastly, the book includes an excellent review on the pros and cons of hormonal therapy in the post-Women's Health Initiative era. This book is a must for gynecologists, psychiatrists, endocrinologists, epidemiologists involved in the clinical care of mature women as well as researchers and students interested in obtaining an up-to-date overview of this topic.
A compelling, “fascinating” (Robert Cialdini) defense of hormone replacement therapy, exposing the faulty science behind its fall from prominence and giving women the evidence they need to make informed decisions about their health. Now fully revised and updated. "Estrogen Matters was my antidote to the misinformation surrounding menopause. This book should be the bible for every single person going through menopause.”―Naomi Watts For years, hormone replacement therapy (HRT) was the medically approved way to alleviate menopausal symptoms (ranging from hot flushes to brain fog) and reduce the risk of heart disease, Alzheimer's, and osteoporosis. But when a large study by the Women's Health Initiative (WHI) announced, with national fanfare, that women taking HRT had an increased risk of breast cancer, women were scared off, and the treatment was abandoned. Now, Dr. Bluming, a medical oncologist, and Dr. Tavris, a social psychologist, reveal the true story of the WHI’s efforts to distort their data to exaggerate unsupported claims of estrogen’s harms. Important updates in this edition include: Evidence that demolishes the WHI’s claim that HRT causes breast cancer. A list of the WHI’s retractions of their original scare stories. Updated findings on estrogen’s benefits on heart, brain, bones, and longevity. A critical review of the alternative products and medications being marketed to treat symptoms of menopause. A sobering and revelatory read, Estrogen Matters sets the record straight on estrogen’s benefits, providing a light to guide women through this inevitable phase of life.
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.